Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy
Elisabeth M. Sulaica(University of Houston), Polly Niravath(Houston Methodist), Raksha R. Bhat(University of Houston), Meghana V. Trivedi(University of Houston), Tiffany Han(University of Houston), Weiqun Wang(Guangzhou University of Chinese Medicine)
Cited by 31
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
The changing role of ER in endocrine resistance
|The Breast|2015|133